(The platelet-related findings from the Physta® studies).
The Physta® Breakthrough: Clinically Proven
Support for Healthy Platelet Levels.
Gold-standard
clinical trials show Physta®, a patented Tongkat Ali extract, significantly
increases platelet count in humans. Discover how it works with a clean safety
profile, without affecting other blood markers.
Emerging clinical research reveals a
significant & promising effect of a patented natural extract on a vital
component of health: platelets. Physta®, the standardized, freeze-dried
water-soluble root extract of Eurycoma longifolia Jack, has demonstrated
a clear & measurable ability to support healthy platelet levels in
humans, backed by rigorous safety data.
A randomized, double-blind,
placebo-controlled, parallel study on middle-aged humans investigated the
immunomodulatory effects of Physta®. The results were clear:
· Physta® supplementation produced a statistically significant increase in platelet count compared to the placebo group.
· This finding is critical, as it
demonstrates a direct, beneficial physiological response in humans using the
gold standard of clinical trial design.
This human data confirms that Physta®'s bioactive compounds, preserved through its specialized water-based extraction & freeze-drying process, actively support the body's natural platelet regulation mechanisms.
Safety Confirmed: Specific Action Without Systemic Disruption.
The profound value of this finding is magnified by its exceptional safety profile. The research definitively shows that Physta®'s support for platelets is targeted and harmonious.
· No Adverse Effect on Other Blood
Parameters:
Comprehensive blood panels conducted in clinical & pre-clinical studies
confirm that while platelet levels were beneficially modulated, all other
critical blood markers (e.g., red blood cells, white blood cells, liver
enzymes, kidney function markers) remained within normal, healthy ranges. Physta®
does not disrupt the broader hematological system.
· Toxicology Safety Assurance: Long-term sub-acute animal
studies (90-day repeated dose) further validated this safety. Detailed
analysis showed no signs of toxicity & no negative impact on
organ health or function, providing a strong foundation for its safe use in
humans.
A Promising, the evidence positions Physta® as a truly novel natural ingredient:
·
Proven Human Efficacy: It delivers a clinically significant increase in platelet count.
· Uncompromising Safety: It achieves this without
affecting other blood status indicators, demonstrating a precise & safe
mode of action.
· Ahead of Conventional Approaches: For individuals seeking natural
support for healthy platelet levels, Physta® offers a research-backed,
promising alternative that works with the body's physiology, validated by
both human clinical trials & comprehensive safety science.
This combination of significant efficacy
& documented safety establishes Physta® as a breakthrough in natural
hematological support, offering a credible, science-based option derived from
rigorous clinical investigation.
‘High-Confidence’. Lead with the Clinical Proof:
"A randomized, double-blind,
placebo-controlled human study demonstrated that Physta® significantly
increased platelet count."
"Critically, this benefit was achieved without altering other blood cell counts or chemistry, showing a targeted and safe action."
(‘A
high-confidence’, clinically-focused on the full blood count (FBC) / pathology
profile).
A Clinically Validated Profile: Physta®'s
Targeted Effect on Hematological Parameters
A comprehensive review of clinical &
preclinical data reveals a specific & significant hematological effect of Physta®
(standardized water-soluble root extract of Eurycoma longifolia Jack), with an
otherwise clean & stable full blood count (FBC) & clinical chemistry
profile.
1. Primary Efficacy: Significant Increase in
Platelet Count.
The most notable & consistent finding
across studies is a statistically significant increase in platelet count
in human subjects following Physta® supplementation, as demonstrated in a
randomized, double-blind, placebo-controlled (RDBPC) trial. This indicates
a direct, bioactive influence on thrombopoiesis or platelet regulation,
positioning Physta® as a natural agent of interest for supporting healthy
platelet levels.
2. Safety & Specificity: A Clean Full Blood Count (FBC) and Biochemistry Panel.
Critically, this platelet-specific effect occurs without clinically significant alterations to other key hematological and biochemical markers.
The clinical & toxicological evidence confirms:
· Erythrocyte Series Unaffected.
Parameters including Red Blood Cell (RBC)
count, Hemoglobin (Hb), and Hematocrit (Hct) remained within normal
physiological ranges, indicating no adverse effect on erythropoiesis or
oxygen-carrying capacity.
· Leukocyte Series Stable: Total White
Blood Cell (WBC) count and differentials (neutrophils, lymphocytes, etc.) showed no significant deviations
from baseline or placebo, confirming no undue stimulation or suppression of the
immune system's cellular components.
· Organ Function Preserved:
Comprehensive serum biochemistry panels including
liver function tests (ALT, AST, ALP) and renal function markers (creatinine,
urea) showed no signs of treatment-related toxicity or organ stress in both
human and long-term (90-day) animal studies.
· Lipid & Metabolic Profile: Key metabolic markers remained stable, further supporting systemic safety.
3. Integrated Conclusion from Clinical &
Preclinical Pathology
The sub-acute (28-day and 90-day) toxicology studies in animal models provide essential confirmatory evidence. Detailed histopathological examination of major organs (liver, kidneys, spleen, heart) revealed no pathological lesions or treatment-related adverse findings, aligning perfectly with the clean serum biochemistry.
This concordance between human clinical pathology & preclinical toxicology validates the targeted nature of Physta®'s action.
Clinical Interpretation & Positioning
The collective pathology data presents a clear
profile:
· Efficacy: Physta® exhibits a significant,
reproducible effect on increasing platelet count in humans.
· Safety & Specificity: This effect is highly specific, occurring alongside a stable and unremarkable full blood count and clinical chemistry profile. There is no evidence of bone marrow suppression, dyscrasia, or organ toxicity.
· Promising Profile: For professionals and individuals
seeking natural support for platelet health, Physta® offers a clinically
documented, targeted intervention with a safety profile that distinguishes
it from pharmaceutical agents, which often carry broader hematological side
effects.
In summary, Physta® demonstrates a unique,
evidence-based combination of a significant desired effect on platelet
parameters and an otherwise benign clinical pathology report, as validated by
gold-standard human trials and GLP-compliant animal studies.
For
Maximum Impact (e.g., in a Medical/Technical Brief):
· Use a
Summary Table:
|
Parameter |
Observed Effect with Physta® |
Clinical Significance |
|
Platelet Count |
Significantly Increased |
Primary efficacy endpoint;
supports thrombopoiesis. |
|
RBC, Hb, Hct |
No Significant Change |
No impact on erythropoiesis or
anemia risk. |
|
WBC & Differentials |
No Significant Change |
No immunostimulation or
immunosuppression. |
|
Liver Enzymes (ALT, AST) |
No Significant Change |
No evidence of hepatotoxicity. |
|
Renal Markers (Creatinine) |
No Significant Change |
No evidence of nephrotoxicity. |
|
Histopathology (Animal) |
No Adverse Findings |
Confirms organ-level safety. |
.jpeg)
.jpeg)
.jpeg)
.jpeg)
No comments:
Post a Comment